Accretion Pharmaceuticals Infotech IPO

About Accretion Pharmaceuticals Infotech IPO

Accretion Pharmaceuticals IPO is a fixed price issue worth ₹29.75 crore. The IPO consists entirely of a fresh issue of 29.46 lakh shares aggregating to ₹29.75 crore. The IPO opens for subscription on May 14, 2025, and will close on May 16, 2025. Allotment is expected to be finalised on May 19, 2025, with tentative listing on the NSE SME platform scheduled for May 21, 2025.

The IPO price is fixed at ₹101 per share. Retail investors must apply for a minimum of 1 lot comprising 1,200 shares, requiring an investment of ₹1,21,200 at the cutoff price. HNI investors are required to apply for at least 2 lots (2400 shares), amounting to ₹2,42,400.

Jawa Capital Services Private Limited is the book-running lead manager for this issue, while Kfin Technologies Limited is the registrar. The market maker is Gretex Share Broking Private Limited.

For detailed financials, company background, and risk factors, investors are advised to refer to the Accretion Pharmaceuticals IPO RHP.

Industry Outlook

1. The Indian pharmaceutical industry plays a crucial role in global healthcare by manufacturing and exporting a wide range of formulations, including tablets, capsules, oral liquids, and external preparations. Companies like Accretion Pharmaceuticals are expanding their footprints across more than 20 countries, including regions in Africa, Southeast Asia, and the Middle East.
2. The sector is supported by certifications like ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005, ensuring compliance with global quality and environmental standards.
3. Demand is driven by both prescription and over-the-counter medicines, along with increasing interest in Ayurvedic and herbal healthcare products aimed at immunity, digestion, and overall wellness.
4. With contract manufacturing also gaining prominence, companies with diversified offerings and robust global networks are positioned to capitalise on rising healthcare needs and expanding pharmaceutical markets. 

Accretion Pharmaceuticals Infotech IPO Objectives 

The company proposes to utilise the net proceeds from the IPO for the following objectives:

1. To strengthen its manufacturing capabilities across product lines such as tablets, capsules, oral liquids, and external preparations.
2. To enhance its contract manufacturing services and scale up production to meet domestic and international demand.
3. To maintain and improve quality standards in line with ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 certifications.
4. To fund general corporate purposes including working capital requirements, marketing efforts, and strategic initiatives for market expansion across more than 20 countries.